Paragen USD Price & Performance (RGENUSD)

Wave Life Sciences has shared promising 48-week data from its FORWARD-53 trial for Duchenne muscular dystrophy. The company plans to file for accelerated FDA approval of WVE-N531 in 2026, leveraging dystrophin expression as a surrogate endpoint. This marks a significant step toward commercialization for the RNA-focused biotech.1

Surrozen has raised $175 million in an oversubscribed private placement to focus on ophthalmology. The funding will support Phase 1 studies for two lead candidates targeting conditions like diabetic retinopathy and AMD. The company is pivoting from liver disease to high-value eye disease markets.2

Unibail-Rodamco-Westfield has successfully issued €815 million in hybrid notes at a 4.875% coupon. The issuance was oversubscribed by more than three times, reflecting strong investor demand. Concurrently, the company launched a tender offer on €995 million of its outstanding hybrid notes, set to expire early next month.3